Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Vol. 102 No. 8 (2017): August, 2017 | Haematologica
Haematologica, Volume 106, Issue 2 by Haematologica - Issuu
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Haematologica, Volume 104, Issue 5 by Haematologica - Issuu
Haematologica, Volume 102, issue 12 by Haematologica - Issuu
Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia | Haematologica
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective | Haematologica
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the Europ
Cancers | Free Full-Text | Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?
Haematologica, Volume 107, Issue 11 by Haematologica - Issuu
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Haematologica, Volume 107, Issue 7 by Haematologica - Issuu
Untitled
Haematologica Atlas of Hematologic Cytology
Haematologica, Volume 105, Issue 10 by Haematologica - Issuu
Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells: Molecular Therapy - Methods & Clinical Development
PDF) Pregnancy outcome in patients with -thalassemia intermedia at two tertiary care centers, in Beirut and Milan | Mohammed Naja - Academia.edu
Vol. 102 No. 4 (2017): April, 2017 | Haematologica
